Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283109 · ClinicalTrials.gov registry record · Phase 1
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
A Phase 1 study of Glioma, Malignant, sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05283109 is a Phase 1 study of Glioma, Malignant that is active but no longer recruiting, run by Mustafa Khasraw, MBChB, MD, FRCP, FRACP. The registered enrollment target is 24 participants, below the 62-participant average among 19 other Glioma, Malignant trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05283109, a Phase 1 study of Glioma, Malignant, is active but no longer recruiting, sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1b study of P30-linked EphA2, CMV pp65, and survivin vaccination (collectively called the P30-EPS vaccine) in HLA-A\*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma.
Conditions Studied
Interventions
- BIOLOGICAL Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine
- DRUG Hiltonol
Study Locations (1)
North Carolina
- The Preston Robert Tisch Brain Tumor Center at Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-08-30 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05283109
The ClinicalTrials.gov registry entry for NCT05283109 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 19 other Glioma, Malignant trials with a reported enrollment target (61% lower). The listed sponsor is Mustafa Khasraw, MBChB, MD, FRCP, FRACP, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma, Malignant appearing as the primary indexed condition, and to 2 interventions - of which Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine is the first listed.
NCT05283109 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05283109 about?
NCT05283109 is a clinical study titled "ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM". This is a phase 1b study of P30-linked EphA2, CMV pp65, and survivin vaccination (collectively called the P30-EPS vaccine) in HLA-A\*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma.
What is the current status of trial NCT05283109?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-08-30. Estimated completion is 2028-02-28.
What conditions does trial NCT05283109 study?
This clinical trial studies the following conditions: Glioma, Malignant.
What interventions are being tested in trial NCT05283109?
The interventions under investigation include: Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine (BIOLOGICAL), Hiltonol (DRUG).
Who is sponsoring clinical trial NCT05283109?
This trial is sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05283109 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma, Malignant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
RECRUITING · Phase 1
-
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma
RECRUITING · Phase 1
-
Imaging of Solid Tumors Using 18F-TRX
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.